Clinical Trial Update: A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral Temanogrel for improving digital blood flow in adults with Raynaud's Phenomenon secondary to systemic sclerosis; the study was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• Temanogrel (Temanogrel)

Snippet

Sponsor: Pfizer | Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2023-12-22